NASDAQ:GLSI
Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. reported net income of −$19.4M in fiscal 2025. The diluted share count rose 4.0%.Summary generated from Greenwich LifeSciences, Inc.'s SEC filings. Latest annual report filed Jun 1, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−3068.2%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+4.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −5 | −8 | −9 | −18 | −19 |
| Net income | −5 | −8 | −9 | −17 | −19 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 4Insider transaction report
Jul 30, 2026 - 4Insider transaction report
Jul 29, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Jun 4, 2026 - 10-KAnnual report for the fiscal year ended Dec 31, 2025
Jun 1, 2026 - 8-KResults of a shareholder vote
Dec 18, 2025 - 10-QQuarterly report for the period ended Sep 30, 2025
Nov 14, 2025 - DEF 14AProxy statement
Nov 3, 2025